Skip to search formSkip to main contentSkip to account menu

olaparib 50 MG Oral Capsule [Lynparza]

Known as: Lynparza 50 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

14 relations
1-ButanolAmmoniaGELLAN GUM (LOW ACYL)Isopropyl Alcohol

Broader (1)

olaparib Oral Capsule [Lynparza]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Metastasiertes Pankreaskarzinom: Progression kann durch zielgerichtete Therapie gestoppt werden
Hintergrund: 4-7% der Patienten mit metastasierten Adenokarzinomen des Pankreas weisen Keimbahnmutationen in den für die DNA… 
Review
2019
Review
2019
Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer
In December 2018, the US Food and Drug Administration (FDA) approved olaparib (Lynparza®), a poly (ADP-ribose) polymerase (PARP… 
2018
2018
Liquid Biopsy korreliert mit Gewebeanalyse
— Vor knapp vier Jahren wurde der PARP(„poly[ADP-ribose]-polymerase“)-Inhibitor Olaparib in der EU für die Erhaltungstherapie von… 
Review
2017
Review
2017
Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer
Approximately 5% of unselected breast cancer patients carry a germline mutation (gBRCAm) in the BRCA1 and BRCA2 genes that… 
2017
2017
Câncer de ovário ganha novo medicamento
O Lynparza® (olaparibe) sera indicado para casos avancados de carcinoma de ovario seroso de alto grau e outros dois tipos de… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)